Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial by Hanley DF et al.
 
 
 
 
 
Newcastle University ePrints | eprint.ncl.ac.uk 
Hanley DF, Thompson RE, Muschelli J, Rosenblum M, McBee N, Lane K, Bistran-
Hall AJ, Mayo SW, Keyl P, Gandhi D, Morgan TC, Ullman N, Mould WA, 
Carhuapoma JR, Kase C, Ziai W, Thompson CB, Yenokyan G, Huang E, Broaddus 
WC, Graham RS, Aldrich EF, Dodd R, Wijman C, Caron JL, Huang J, Camarata P, 
Mendelow AD, Gregson B, Janis S, Vespa P, Martin N, Awad I, Zuccarello M, 
MISTIE Investigators. Safety and efficacy of minimally invasive surgery plus 
alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, 
controlled, open-label, phase 2 trial. Lancet Neurology 2016, 15(12), 1228–
1237.
DOI link 
http://dx.doi.org/10.1016/S1474-4422(16)30234-4  
ePrints link 
http://eprint.ncl.ac.uk/pub_details2.aspx?pub_id=229960  
Date deposited 
25/01/2018 
Copyright 
© 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
 
Licence 
This work is licensed under a  
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence 
 
 
Safety and efficacy of minimally invasive surgery plus 
recombinant tissue plasminogen activator in intracerebral 
haemorrhage evacuation (MISTIE): a randomised, phase 2 trial
Daniel F. Hanley, Richard E. Thompson, John Muschelli, Michael Rosenblum, Nichol 
McBee, Karen Lane, Amanda J. Bistran-Hall, Steven W. Mayo, Penelope Keyl, Dheeraj 
Gandhi, Tim C. Morgan, Natalie Ullman, W. Andrew Mould, J. Ricardo Carhuapoma, Carlos 
Kase, Wendy Ziai, Carol B. Thompson, Gayane Yenokyan, Emily Huang, William C. 
Broaddus, R. Scott Graham, E. Francois Aldrich, Robert Dodd, Cristanne Wijman, Jean-
Louis Caron, Judy Huang, Paul Camarata, A. David Mendelow, Barbara Gregson, Scott 
Janis, Paul Vespa, Neil Martin, Issam Awad†, Mario Zuccarello†, and for the MISTIE II 
Investigators*
Department of Neurology, Brain Injury Outcomes (BIOS) Coordinating Center (Prof DF Hanley, 
MD, N McBee, MPH, K Lane, CMA, A Bistran-Hall, BS, P Keyl, PhD, T Morgan, MPH, N Ullman, 
MPH, WA Mould, BA, JR Carhuapoma, MD, W Ziai, MD) and Department of Neurosurgery (J 
Huang, MD) and Department of Biostatistics, School of Public Health (RE Thompson, PhD, J 
Muschelli, PhD, M Rosenblum, PhD, CB Thompson, MS, G Yenokyan, PhD, E Huang, PhDc); 
Johns Hopkins University, Baltimore, MD; Emissary International, LLC, Austin, TX (SW Mayo, 
PD); Department of Neuroradiology (D Gandhi, MD) and Department of Neurosurgery (EF 
This manuscript version is made available under the CC BY-NC-ND 4.0 license.
Corresponding author: Prof Daniel F. Hanley, Acute Care Neurology, Johns Hopkins University, Division of Brain Injury Outcomes, 
1550 Orleans Street, 3M50 South Baltimore, MD 21231, USA, dhanley@jhmi.edu.
*A complete list of investigators in the MISTIE II trial is provided in the Supplementary Appendix.†Contributed equally
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Contributions. DFH and MZ organized the trial hypotheses, designed the trial, and provided guidance about the data analysis and 
interpretation/presentation of the data. DFH drafted most of the sections of the manuscript. EFA, CW, WCB, RSG, RD, JLC, JH, PC, 
PV, NM, IA, ADM, BG, PK, KL, and NMcB were involved in the design of the study and provided contributions to the writing and 
revising of the manuscript. KL, NMcB, SWM, and AJBH organized and managed the trial including trial start-up, data collection, 
quality assurance, and trial close-out. DG, TCM, NU, and WAM provided the region of interest calculations for all volumetric 
measurement results. WZ, CK, and JRC provided independent review and adjudication of all safety events. RET, JM, MR, CBT, GY, 
and EH were involved in the statistical analysis, data interpretation, and contributed to the development and revisions to the 
manuscript. SJ provided critical review of the manuscript. The MISTIE II investigators contributed equally to the identification and, 
when eligible, randomization of trial participants.
Declaration of Interests. IA, DFH, SWM, NU, KL, NMc, WAM, MR (R01NS046309 and U01NS062851), CBT, and PV report 
grants from the National Institute of Neurological Disorders and Stroke (NINDS) during the conduct of the study. DFH reports non-
financial support from Genentech and Johnson& Johnson (Codman) during the conduct of the study, grants from NINDS outside the 
submitted work, and expert testimony. SWM reports personal fees from Johns Hopkins University outside the submitted work. JM 
reports grants from the National Institutes of Health during the conduct of the study and has a patent (C13388—primary intracerebral 
haemorrhage prediction employing logistic regression and features extracted from CT) pending for Johns Hopkins. ADM reports 
grants from the National Institutes of Health during the conduct of the study, non-financial support as the Director of the Newcastle 
Neurosurgery Foundation, and personal fees from Advisor to Stryker and Draeger outside the submitted work. BG reports grants from 
Johns Hopkins University (MISTIE National Institutes of Health grant) during the conduct of the study and grants from the National 
Institutes of Health Research (UK) Health Technology Assessment Programme outside the submitted work. All other authors declare 
no competing interests.
HHS Public Access
Author manuscript
Lancet Neurol. Author manuscript; available in PMC 2017 November 01.
Published in final edited form as:
Lancet Neurol. 2016 November ; 15(12): 1228–1237. doi:10.1016/S1474-4422(16)30234-4.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Aldrich, MD), University of Maryland, Baltimore, MD; Department of Neurology, Boston University, 
Boston, MA (C Kase, MD); Department of Neurology (W Broaddus, MD) and Department of 
Neurosurgery (RS Graham, MD), Virginia Commonwealth University, Richmond, VA; Department 
of Neurology (C Wijman, MD) and Department of Neurosurgery (R Dodd, MD), Stanford 
University, Palo Alto, CA; Department of Neurosurgery, University of Texas, San Antonio, San 
Antonio, TX (JL Caron, MD); Department of Neurosurgery, University of Kansas, Kansas City, KS 
(P Camarata, MD); National Institutes of Health, National Institute of Neurological Disorders and 
Stroke, Bethesda, MD (S Janis, PhD); Department of Neurology (P Vespa, MD) and Department 
of Neurosurgery (N Martin, MD), University of California, Los Angeles, Los Angeles, CA; 
Department of Neurosurgery, University of Chicago, Chicago, IL (Prof I Awad, MD); Department 
of Neurosurgery, University of Cincinnati, Cincinnati, OH (Prof M Zuccarello, MD). Neurosurgery, 
Newcastle University, Newcastle upon Tyne, UK (A D Mendelow FRCS[SN], B Gregson PhD)
SUMMARY
Background—Craniotomy, when evaluated in trials, does not improve outcome after 
intracerebral haemorrhage (ICH). Whether minimally invasive catheter evacuation followed by 
thrombolysis is safe and can achieve a good functional outcome by removing clot is unknown. We 
investigated safety and efficacy of alteplase with minimally invasive surgery (MIS) in patients with 
intracerebral haemorrhage.
Methods—MISTIE was an international, randomized, open-label study and was done in 26 
hospitals in the USA, Canada, the UK, and Germany. Patients (aged 18–80 years), with non-
traumatic (spontaneous) ICH ≥20 mL were randomly allocated, centrally, to medical care or 
image-guided MIS plus rt-PA (0.3 mg or 1.0 mg every 8 hours for up to 9 doses) to remove clot 
using surgical aspiration followed with alteplase clot irrigation. The primary efficacy outcome was 
the adjusted dichotomized modified Rankin Scale (mRS) 0–3 vs 4–6 assessed at day 180 after 
symptom onset. Analysis was by intention to treat. (ClinicalTrials.gov number NCT00224770).
Findings—Between February 2, 2006 and April 8, 2013, 96 subjects were randomized and 
completed follow-up: 54 received treatment and 42 medical care. Primary safety outcomes: 
mortality, symptomatic bleeding, brain infections, as well as withdrawal of care, did not differ 
between groups. Asymptomatic hemorrhages were more common in the surgical group (3 (7%) vs. 
12 (22%) p= 0.05) producing a difference of 15.1% (95% CI: 1.5% to 28.6%). The estimated 
absolute benefit, i.e., the unadjusted difference in observed proportions of all subjects with mRS 
0–3 (33% vs 21%) at 180 days comparing MISPA vs. medical control, is 0.109 [95%CI: −0.088, 
0.294; p=0.26], and is 0.162 [95%CI: 0.003, 0.323; p=0.05] after adjustment for potential 
imbalances in baseline severity between study arms (primary efficacy outcome).
Interpretation—MIS+rt-PA appears safe with an apparent advantage of better functional 
outcome at 180 days. Increased asymptomatic bleeding is a major cautionary finding. The MISTIE 
trial results, if replicable, could produce a meaningful functional benefit adding surgical 
management as a therapeutic strategy for ICH.
Funding—National Institute of Neurologic Disorders and Stroke, Genentech, and Codman.
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Introduction
Brain haemorrhage affects more than 5 million people each year.1 It is the most severe form 
of stroke for which there is no evidence-based primary treatment.2–4 Well executed 
pragmatic trials of therapy used in routine practice have not shown that any treatment 
substantially reduces haematoma size and brain tissue damage, and improves functional 
outcome. In the STICH (Surgical Treatment for Intracerebral Hemorrhage) I and II trials, 
routine craniotomy did not show an alteration of functional outcomes.5,6 STICH I suggested 
clot removal may simplify and shorten overall medical care,5 and STICH II demonstrated a 
non-significant 5.6% decrease in mortality. Nonsurgical trials of aggressive, early 
haemostasis,7 showed some stabilisation of haematoma growth but no change in functional 
outcome. In the large INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral 
Haemorrhage Trial) II trial, early blood pressure (BP) lowering reduced clot growth by a 
small amount and led to a nonsignificant, 3.7%, gain in functional outcome.8 The MISTIE II 
trial was designed to assess alteplase (Alteplase, Genentech, South San Francisco, CA, 
USA) dose response (stage one) and whether minimally invasive surgery (MIS) followed by 
thrombolytic treatment is safe and reduces, and perhaps reverses, the burden of clot on tissue 
(stage two)9,10 and to provide preliminary functional outcome data.10–15
Methods
Study Design
MISTIE II was an international, multicenter (26 sites in the USA, Canada, UK, and 
Germany), randomized, phase 2 trial16 of image-guided,14 catheter-based13 removal of ICH 
≥20 mL, measured by the ABC/2 method.17 All subjects were managed in an intensive care 
unit setting. Local institutional review board (or Ethics Committee) approval was obtained at 
each hospital.
Participants
Subjects with non-traumatic (spontaneous) ICH attributed to cerebral small vessel disease 
and not due to a macrovascular cause such as an aneurysm or AVM were candidates for this 
trial. After obtaining written, informed consent, all patients age 18–80 years old with 
spontaneous, non-traumatic, supratentorial ICH ≥20mL, Glasgow Coma Scale (GCS) score 
≤14 or NIH Stroke Scale (NIHSS) score ≥6, a historical modified Rankin Scale (mRS) score 
of 0 or 1, whose ICH remained the same size for ≥ 6hrs and who satisfied all other inclusion/
exclusion criteria listed in the Supplemental Appendix (page 4) were randomized.
Randomization and Blinding
Patients were randomized by local site personnel using a central web-based enrollment 
system. The trial statistician employed a randomly generated number sequence to allocate 
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patients to the surgical and medical groups. Patient allocation was stratified according to clot 
size with two schedules employed: one for ICH ≥20 mL and ≤40 mL; and one for ICH >40 
mL as measured on the diagnostic CT. The trial had two pre-planned stages, which were 
managed by an independent data safety monitoring board (DSMB): a dose finding stage and 
a safety assessment stage. Stage one (dose finding) consisted of two doses (0.3mg and 
1.0mg). A third dose, 3mg, was not investigated after a planned DSMB review. This decision 
decreased the sample size from 110 to 96 subjects. Subjects in stage 1 were randomized 3:1 
to treatment (MIS plus the dose of rt-PA in that part) or medical management. In stage one 
only, blocks of 4 patients were employed within each randomization schedule to ensure a 3:1 
assignment to treatment (MIS+rt-PA) versus control (medical management). After stage one 
enrollment and DSMB review were completed, a planned protocol amendment, occurred. 
This specified the use of alteplase at the selected 1 mg dose (based on safety profile and clot 
removal efficiency), use of a surgical oversight center (based on initial surgical performance) 
and addition of 365 day outcome assessments. This amendment was reviewed and approved 
by the DSMB and executive committee. Stage two remained stratified by size, used 1:1 
randomization and evaluated the safety of treatment vs. medical management.
The first subject at every site was assigned to surgical management and served as a 
“credentialing subject” to document the surgeon’s ability to perform the surgical protocol. 
Once a surgeon was credentialed, subsequent eligible patients were randomized to MIS+rt-
PA or medical management (stage one: 3:1; stage two: 1:1). The assignments were not 
masked because of surgical assignment in the protocol. The number randomized in stage one 
was 29 to MIS+rt-PA and 17 to medical management; the corresponding numbers in stage 
two are 25 to MIS+rt-PA and 25 to medical management. Unlike stage one participants 
(followed up to 180 days), stage two participants were followed up for 365 days. The site 
examiners performing the outcome assessments were masked to treatment assignment.
Procedures
Stability Protocol
The risks of initial haematoma growth/instability were managed by use of a stability 
protocol combining normalization of coagulation parameters, BP management, and repeat 
computed tomography (CT) assessment of clot size, measured using the ABC/2 method. Six 
or more hours after the diagnostic CT, a stability CT was performed to ensure that the ICH 
clot had not expanded by >5 mL, providing image demonstration of a safe starting point for 
clot reduction therapy, defined as the absence of active bleeding before performing MIS+rt-
PA. The CT could be repeated every six hours until the clot stabilized or just before the 48-
hour eligibility window closed, whichever came first. In addition, a magnetic resonance 
image (MRI) or CT angiography (CTA) was required to rule out underlying pathology as the 
bleeding source; an angiogram was encouraged with equivocal findings on vascular 
pathology screening.17 An INR ≤1.3, a normal aPTT, and BP stability were required prior to 
randomization.18,19 After a protocol amendment, planned catheter insertion trajectories 
describing the skull entry site and the planned linear path to the hematoma target were 
shared by the site with the trial’s Surgical Center for joint review (stage two only).
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MIS Protocol
Individuals randomized to MIS+rt-PA were taken to the operating room and general 
anesthesia was induced. Image-guidance was used to place an introducer cannula within the 
middle two-thirds of the overall haematoma diameter, via a burr hole or twist drill opening. 
The introducer portion was then removed. Clot aspiration was performed using a 10 mL 
hand-held syringe until there was no longer any fluid component of the clot noted in the 
aspirate and/or until first resistance. A soft catheter was passed through a rigid, peel-away 
cannula into the residual haematoma, tunneled subcutaneously, and connected to a three-way 
stopcock and a closed drainage system. A postoperative CT was performed to confirm 
positioning of the soft catheter within, and stability of, the residual haematoma and catheter 
tract.
Thrombolysis Protocol
Three or more hours after catheter placement, intraclot rt-PA administrations of 0.3 mg in 1 
mL or 1.0 mg in 1 mL were given every 8 hours, for up to 9 doses, or until a trial-defined 
surgical performance requirement was reached. All doses were followed by a 3 mL flush of 
preservative-free normal saline. After each assigned dose, the system was closed for 1 hour 
to allow drug-clot interaction, and then reopened to allow for gravitational drainage. Trial-
defined surgical performance requirements were reduction of clot to either 20% of the 
volume measured on the stability CT prior to randomization, or to ≤ 15 mL, or occurrence of 
a clinically significant re-bleeding event, defined as a sustained drop of more than two points 
on the Glasgow Coma Scale (GCS) motor score with CT-demonstrated ICH enlargement. 
CT scans were subsequently obtained every 24 hours until dosing was complete to evaluate 
safety and drainage.
Medical Treatment Protocol
All subjects were managed using the American Heart Association recommendations for the 
treatment of non-traumatic (spontaneous) ICH.18–19 This allowed for a standard approach to 
monitoring patients’ airway, ventilation, intracranial pressure (ICP), sedation, and 
pharmacological treatment of intracranial mass effect. Patients randomized to receive 
standard medical care received follow up CT scans and other monitoring assessments on the 
same schedule as those randomized to receive MIS+rt-PA.
Follow-up
Subjects were followed with an MRI scan at Day 7. Subjects returned to clinic on Days 30, 
180 (stages one and two), and 365 (stage two) and were contacted by phone at Days 90 
(stages one and two) and 270 (stage two). A certified examiner assessed the modified 
Rankin Scale (mRS), Barthel Index (BI), Stroke Impact Scale (SIS), Glasgow Outcome 
Scale (GOS), extended GOS (eGOS), NIH Stroke Scale (NIHSS, clinic visits only) and a 
repeat CT (days 30 and 180 only).
Image analysis
To optimize accuracy and minimize investigator bias, clot volumes were analyzed by a core 
laboratory utilizing semi-automated segmentation and Hounsfield thresholds.9 This was 
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performed using OsiriX software (version 4.1) on DICOM images of each subject’s stability 
and treatment scans. This approach has been validated for accuracy and inter-rater 
reliability.20 The core lab values were utilized in all analyses. Core lab defined location as 
either lobar or deep (putamen or thalamus).
Primary and Secondary Outcomes
The aim of the MIS+rt-PA treatment was to achieve near total clot dissolution without 
procedure-related safety events that would endanger the lives of the patients beyond the risks 
associated with intensive medical treatment. The primary safety outcomes were 30-day 
mortality, 7-day procedure-related mortality, 30-day bacterial brain infection, and 
symptomatic bleeding within 72-hour after the last dose. The primary efficacy outcome was 
the adjusted 180-day dichotomized (mRS 0–3 vs. 4–6.) expressed as the proportion of all 
mRS subjects ≤3.
Secondary efficacy outcomes were 180-day ordinal mRS, 365-day ordinal mRS, and 
difference in clot-size reduction at the end of the treatment for each group. All adverse and 
serious adverse events were reported during the acute treatment period and all serious 
adverse events until the end of the follow-up.
Statistical analysis
Analyses are presented at three levels: primary planned safety analysis, primary intention to 
treat efficacy analysis, and exploratory analyses. The latter two are adjusted analyses.16
Target Sample Size
The study was designed and powered to explore safety and dosing for MIS+rt-PA. It was not 
powered to observe effect of treatment on functional outcome. This study had 90% power to 
detect a doubling in the rate of any rebleeding from 8% to 16% between dose groups of 15 
subjects who received the MIS+rt-PA intervention at each dose level. The study had 80% 
power to detect a difference in rates of clot dissolution of 3% per day or greater, between 
groups of 15 subjects on different doses of rt-PA (stage one). It had a 91% to 99% power to 
observe one or more symptomatic bleeds for 15 subjects if the true bleeding rate was 15%. 
For stages one and two combined, assuming a total of 80 subjects, it had from 52% to 62% 
power to detect an absolute difference of 25% in the mortality rate assuming a 50% 
mortality rate. The target sample size for stage one was 20 subjects per dose group and for 
stages one and two combined the final target sample size was a total of 96 subjects.
Safety Analysis
Analyses tested the hypothesis that there was no difference between the treatments being 
compared. We defined and pre-specified thresholds for the safe use of MIS+rt-PA for the 
treatment of ICH relative to standard medical care: for 30-day mortality (70%), symptomatic 
brain bleeding (35%), and bacterial brain infection (15%). We tested rates of events across 
groups by Fisher’s exact test and calculated exact binomial 95% confidence intervals (CI) 
for the rate of events. The method of Kaplan and Meier was used to estimate the survival 
functions (with 95% CI) for patients in both groups.
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Intention-to-Treat Efficacy Analysis
We estimated the mean benefit of MISTIE treatment vs. medical control using the ITT 
principle. Specifically, we estimated the difference between the probability of having 180-
day mRS ≤3, referred to as a good outcome, under treatment vs. control. This average 
treatment effect was estimated using a simple difference in proportions among those with 
observed 180-day outcomes (unadjusted estimator) and also using an estimator that adjusts 
(adjusted estimator) for missing outcome data using the double-robust methodology for 
censored data of Rotnitzky et al.21,22 The adjusted estimator is fully described in the 
appendix (page 10); it has greater precision than the unadjusted estimator because of 
adjustments for potential imbalances between study arms in the prognostic baseline 
covariates: NIHSS, GCS, ICH volume, and intraventricular haemorrhage (IVH) volume.21
Exploratory Analyses
Patient characteristics, safety, and outcome measures were reported by each site. To describe 
medical events we utilized terms and definitions from the Medical Dictionary for Regulatory 
Activities (MedDRA) and centrally adjudicated. Longitudinal plots were used to depict the 
percent ICH clot reduction from stability over time for each participant. LOESS (locally 
weighted scatter-plot smoothing) was applied to calculate mean clot reduction over time by 
treatment group.23
To investigate the role of clot volume reduction by MIS+rt-PA on outcome, we used logistic 
regression models to estimate the association between the primary outcome measure of 
dichotomized 180-day modified Rankin Scores ≤3 with treatment group, clot removal, and 
the baseline variables identified in the study protocol24: ICH clot size at randomisation, age, 
enrollment NIHSS, presence of IVH, and location of ICH. The multivariable logistic 
regression models were created by first considering univariable analyses to determine the 
independent associations between each covariate and the outcome. For parsimony, the 
variables chosen for the multivariable regression analyses, in addition to treatment, were 
those with p<0.1 in the univariable analyses; these variables are similar to those from 
previous ICH studies.6,8,25 Other prespecified baseline variables that were non-significant in 
the univariate analyses were systematically considered as candidate explanatory variables in 
the multivariate analysis, for the purpose of hypothesis generation. As in any variable 
selection method for model building, our approach has limitations and should be regarded as 
exploratory; see Sauerbrei et al.26 for a discussion of model building approaches. Sensitivity 
analyses were performed that considered all possible ‘good’ and ‘bad’ outcomes for patients 
with missing 180-day mRS scores to determine a possible tipping point that would change 
the statistical association between the outcome and clot removal.27,28 Logistic regression 
was used for sensitivity analyses of subgroups.
Surgical Removal
To manage the influence of time on the subjects, we defined volume of clot removed at the 
specific times defined as follows: for patients in the MIS+rt-PA arm, the end of treatment 
(EOT) was defined to be 24 hours after the last dose of rt-PA was administered; the EOT 
scan for patients in the medical management arm was defined as the scan closest to the 
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median EOT scan time for the surgical patients (4 days post randomization).9 The EOT scan 
among patients who received delayed craniotomy in the medical management arm was 
defined, on an ITT basis, as the scan prior to craniotomy. All analyses were performed using 
the statistical packages STATA (version 12.0) and R (version 3.2). The trial was registered 
on clinicaltrials.gov (NCT00224770).
Role of the funding source
The NIH/NINDS provided input regarding the study design during the grant review process 
and the NIH/NINDS-appointed DSMB provided the same during active recruitment. The 
NIH/NINDS-appointed DSMB and Genentech, Inc. approved the decision to submit the 
paper for publication. DFH had full access to all study data and had final responsibility for 
the decision to submit for publication.
Results
The trial ended after target enrollment was achieved. Study enrollment for stage one took 
place from February 2, 2006 to August 2, 2009. (See Fig.1). Stage two enrollments took 
place from December 21, 2009 through April 3, 2012, with the final follow-up visit 
occurring on April 8, 2013 after approval of the planned protocol amendment. The 
demographic characteristics of the randomized subjects are shown in Table 1. Fifty-four 
subjects (stages one and two combined) were randomized to the intervention: eight (15%) 
achieved the surgical goal at the end of the surgical procedure (i.e., after aspiration and 
catheter placement, and 46 (85%) received rt-PA via the catheter to further reduce the 
haematoma size (MIS+rt-PA). Forty-two subjects (stages one and two combined plus 6 
subjects from stage one endoscopy arm) were randomized to medical care. Delayed 
deterioration led to craniotomy in four medical and in two MIS+rt-PA subjects (post MIS 
procedure). Overall, event rates were below pre-specified safety thresholds and the primary 
safety profile of symptomatic events was similar for both groups (Table 2). The entire 
surgical group had non-significantly more asymptomatic and significantly more total 
bleeding (Table 2). Kaplan-Meier analysis of survival over 365 days demonstrated no 
adverse effect of MIS+rt-PA on survival (hazard ratio 1.32 (95% CI: 0.618, 2.82) log rank 
p=0.473); see Figure S1 on page 13 in the Supplementary Appendix). Those randomized to 
the treatment arm achieved more rapid ICH volume reduction when compared to the 
standard medical care group (Fig. 2). Thirty-one of thirty-five neurosurgeons easily acquired 
the technical skills (87% training efficiency). There were no differences in volume of clot 
removed between a surgeon’s 1st and 4th procedure performed or between “neophyte” and 
“expert” surgeon (data not shown).
Both rt-PA doses increased clot removal, when compared to the control group, with no 
differences in symptomatic bleeding rate 0 (0%) vs. 2 (13%) for 1.0. mg vs 0.3 mg, 
respectively and 1 (2%) for control (difference between doses 95% CI: −3.87%, 30.54%; 
p=0.483); leading to the selection of the 1.0 mg dose for stage two (Table S6, appendix page 
22). Overall, for both stages one and two symptomatic bleeding was 1 (2%) vs. 5 (9%); 
difference between treatment groups 6.9% (95%CI: 4.6%, 18.1%; p=0.2263). Reduction of 
clot volume over time and for the ITT analysis at about Day 4 is shown in Figure 2. Overall, 
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the mean (SD) percent reduction of haematoma size (EOT ICH/Randomization ICH) in the 
MIS+rt-PA group was 57% (± 25%). The mean (SD) EOT ICH was 20 (± 14) mL in the 
MIS+rt-PA subjects and 41 (± 15) mL p< 0.0001 in the medical management subjects (mean 
[95% CI] difference: 21 [15mL, 27 mL]).
Results: ITT Efficacy Analysis
The primary efficacy outcome was the proportion of all subjects with mRS ≤3 at 180 days 
was 21% for medical and 33% for MIS arms. The unadjusted estimate of the absolute 
benefit (i.e., the difference between the probability of having 180 day mRS ≤ 3 under 
treatment vs. control) is 0.109 [95%CI: −0.088, 0.294], based on the n=96 ITT randomized 
participants. The adjusted estimate using the robust method of Rotnitzky et al.21,22 is an 
absolute benefit of 0.162 [95%CI: 0.003, 0.323].
A secondary outcome was mRS ≤3 at 365 days which was only measured for stage two 
participants (n=56, who had extended follow-up). The unadjusted estimate of the absolute 
benefit at 365 days is 0.117 [95%CI: −0.146, 0.370] and the adjusted estimate was and 0.115 
[95%CI: −0.171, 0.306].
Additional secondary analyses focus on ordinal (rather than dichotomous) mRS scores. The 
proportion in each mRS category at 180 days (stages one and two participants) and at 365 
days (stage two participants only) is shown in Table 3 demonstrating the beneficial trend is 
maintained at the later time frame.
Results: Exploratory Analyses
Results of the logistic regression analysis on the binary indicator good vs. unfavorable mRS 
scores are presented in Table S1 on page 17 of the Supplementary Appendix. When we 
considered univariable (unadjusted) models, we found that pre-randomized ICH volume, 
age, enrollment NIHSS, the presence of any pre-randomization IVH, and the absolute clot 
volume remaining at the EOT were statistically significant; assignment to MIS+rt-PA 
resulted in a nonsignificant benefit (similar to the estimates in the ITT efficacy analysis 
above). Table S1 shows the results of the multivariable logistic regression of good 180-day 
outcome on the aforementioned variables. After controlling for age, enrollment NIHSS, pre-
randomized ICH volume and presence of IVH, and assignment to MIS+rt-PA, the absolute 
volume of clot remaining at the EOT is statistically significant. Specifically, the model 
predicts that with all other variables held constant, each 10 mL of additional clot remaining 
at the end of treatment is associated with a relative reduction in the odds of a good 180-day 
outcome by almost 50% (Adjusted Odds Ratio 0.496; [95%CI] 0.259, 0.949, p= 0.034). This 
is consistent with the hypothesis that clot volume reduction is an important mechanism 
through which assignment to MIS+rt-PA results in greater probability of mRS ≤3 at 180 
days. Unadjusted ITT analyses in different subgroups are shown in Figure S2 on page14 of 
the Supplementary Appendix. There were no statistically significant results by subgroup, but 
all point estimates are in the beneficial direction of the MIS+rt-PA treatment compared to 
medical management and the point estimate for deep clot location corresponds to greater 
benefit than for lobar clot location, although again not statistically significant.
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Discussion
MIS+rt-PA appears safe when tested in our phase 2 study, with a possible advantage of 
better functional outcome at 180 days. However, increased asymptomatic bleeding is a major 
cautionary finding. MISTIE II is an important test of a very gentle approach to ICH 
evacuation, minimizing potential tissue injury inherent in craniotomy. It employs image 
guidance and a novel combination of surgery and drug treatment. The MISTIE II approach 
was reliably reproduced by surgeons new to the treatment concept but trained in the general 
principles. The surgical technique is a simple and logical extension of routine image 
guidance and intracerebral catheter placement. Where both pragmatic (craniotomy) and 
simple translational (factor VIIa) approaches have failed in trials, our results are promising 
and contrary to the belief that surgical manipulations to remove blood may damage brain 
tissue and impair long-term function.5,29,30 Because supportive medical care is the only 
universally-accepted ICH treatment, these results are promising19,30 and consistent with 
trends from studies of convenience samples or at single sites.31,32 We have demonstrated 
that MIS can be performed safely at multiple sites, that rt-PA can be combined with MIS 
safely, and that the MISTIE treatment, though different from current practice, can be 
adopted without difficulty at interested sites. Thus, MISTIE could be a promising approach 
to a worldwide health problem. If the apparent benefits of the MISTIE approach are 
replicable, the findings could lead to a change in treatment of ICH.
Several limitations are considered. This trial size is small and screening yield low (123 
enrolled of 4103 screened). It was powered to observe relatively high safety thresholds (15% 
bleeding), not efficacy; thus, the range of estimated benefit in the ITT analysis is wide and 
the true benefit could be different. However, all known baseline severity factors (ICH size, 
IVH size, age, NIHSS, GCS and stability) were nearly balanced between arms. The point 
estimates in both adjusted ITT analyses are suggestive of a treatment benefit. Safety 
conclusions are similarly limited by sample size; the substantial difference in asymptomatic 
bleeding demonstrates that combining MIS and alteplase still has important risks.
We hypothesize that the effect of the MISTIE treatment on mRS outcome is mediated 
through clot volume reduction, although such a relationship cannot be assessed without a 
second trial. We considered potential confounders of the relation between clot-reduction and 
mRS outcomes, such as length of ICU care and use of ICP monitoring; these were similar in 
both treatment groups. Surgical bias could unknowingly account for good outcomes; 
however, the usual source of this problem—selection of less severe subjects for surgery—did 
not occur, as the randomized surgical subjects were slightly, but non-significantly, more 
impaired at baseline, and all subjects were consented without knowledge of surgical 
allocation, further limiting the possibility of surgical selection bias. A bias could also be that 
the population was not fully representative of the general population of ICH subjects and 
that the routine care that medical management subjects received may account for the surgical 
benefit by having selected a sicker subgroup. This is not likely, as the distribution of good 
and poor outcomes for the medical subjects is similar to that found in observations of other 
ICH populations. A bias in the amount of rehabilitation care a particular group received is 
also possible. Finally it remains possible that specialized skills, such as surgical skill or 
superior stroke center organizational resources produced the benefits rather than the MISTIE 
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treatment, rendering the results not reproducible by a wider set of surgeons or centers. This 
seems unlikely, as the majority of the surgeons, although trained in image guidance and 
catheter placement, previously had not combined these skills to treat ICH. Similarly, 
attention to BP control in MISTIE is already a well-developed and standard approach in 
established stroke center protocols.8,18,23,25,33
Our outcome data suggest that MIS+rt-PA has the potential to be efficacious where routine 
craniotomy has failed. Comparisons to existing trial data31 and meta-analysis data32,34,35 are 
reassuring for the possible generalizability of these findings. Mortality was low and not 
different for medical or surgical subjects and was similar to STICH I & II mortalities,36,37 
suggesting that the surgical procedure itself is low risk. This is in agreement with other MIS 
observations.32 The low mortality may relate to the infrequent discontinuation of care. 
Interestingly, the deep ICHs that responded so poorly to invasive craniotomy in STICH I 
appear to have benefitted from MIS plus rt-PA.
Administration of rt-PA following MIS also appears safe in this small sample utilizing 
mortality and symptomatic bleeding as the main safety measures, but only if performed 
under MISTIE protocol conditions. Some rebleeding must be expected in ICH patients and 
with exposure to surgery and thrombolytic drug. The significantly increased occurrence of 
asymptomatic bleeding provides biologic plausibility for further safety evaluations. The 
combined use of imaging to define clot stability and BP control appears to have limited the 
frequency of symptomatic bleeding events in both arms of MISTIE and the absence of a 
symptomatic rebleeding difference between MIS+rt-PA and controls is a reassuring safety 
profile for a thrombolytic treatment approach; external monitoring and core imaging lab 
assessments for enlargement reinforce our confidence in this safety profile. However, the 
presence of higher frequencies for all bleeding categories in the treatment arm demonstrates 
that the possible benefits of MIS+rt-PA come with a clear potential bleeding risk that must 
be managed with clinical vigilance. A larger sample is needed to confirm that the current 
clinical vigilance (ICH stability, dose and BP control) is reproducible in the widest possible 
population. A phase 3 study would provide a better estimate of safety and particularly 
bleeding events.
The MISTIE approach targets two major sources of ICH morbidity: mass effect and 
inflammation. The functional outcomes in the treatment group are consistent with better 
tissue preservation9,10 and, when compared to the medical management group equally 
treated with ICH stabilization and BP control, reassuring for the potential to reproduce the 
result in other populations. The trial design was not able to differentiate whether better tissue 
preservation was attributable to mass-effect reduction or to removal of inflammation-
provoking blood products; most likely both are important effects of clot reduction. Because 
removal took place over three to four days, it is likely that some degree of secondary injury 
from mass effect and inflammation occurs over days, not hours. If the MISTIE approach of 
minimal mechanical manipulation is to be employed the majority of subjects (85%) will 
require rt-PA irrigation to achieve large reductions of clot volume. Analysis of subgroups 
suggests the potential for benefit in a window of at least 48 hours. If the time window is this 
large, then MISTIE treatment could possibly be scheduled urgently rather than in an 
emergent manner. The model and subgroup findings represent hypothesis generating 
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information such as time dependence of treatment and require independent confirmation. For 
example if much damage occurs by chemical means in the initial hours there could be 
additional benefit to very early removal or biochemical blockade of such events.
Testing the reproducibility of our results will require at least 500 subjects in a randomized 
trial; possibly more, if the estimate of therapeutic effect is falsely large or if the symptomatic 
bleeding risk is underestimated. A rigorous test should include stringent reproduction of the 
standard elements of the surgical and drug-administration tasks used in MISTIE II in a 
cohort of subjects recruited from the widest possible set of stroke hospitals utilizing image 
guidance, CT imaging, and BP control to treat ICH. Decreases (s) in treatment related 
bleeding events might benefit outcome. Testing generalisability will provide a better 
estimate of the number of treatment candidates. Safety and preliminary outcome data 
indicate that MIS+rt-PA is a realistic approach to ICH, possibly improving long-term 
function and the ability to live at home, and perhaps, decreasing cost, even for patients with 
large ICH volumes.
Panel: Research in Context
Evidence before this study
Minimally invasive surgery was reviewed in a recent meta-analysis by Zhou et al. This 
review of international databases, websites, and conference summaries such as Pubmed and 
the International Clinical Trials Registry were searched through December 2011 using the 
following key words: intracerebral, intracranial, cerebral, brain, putaminal, 
intraparenchymal, basal ganglia hemorrhage, thalamic, hemorrhagic stroke, hemorrhage, 
hematoma, minimally invasive, minimal surgical procedures, endoscopy, stereotaxy(ic), 
aspiration, keyhole, or craniopuncture. Inclusion criteria were nontraumatic (spontaneous) 
ICH diagnosed on a CT and randomized controlled trials with minimally invasive surgery 
compared to a control group. Exclusion criteria were traumatic brain injuries, infratentorial 
ICH, and studies with quality assessments less than 2 on the Cochrane criteria scale. An 
Egger test was conducted to check for publication bias for primary and secondary outcomes 
(P=0.377 and P=0.805 respectively).
We have thirty years of evidence that clinical injury from ICH is directly related to the size 
of the clot. Benefit from the obvious solution of reducing the clot size by mechanical means 
has been difficult to demonstrate. Now with the completion of STICH 1 & 2, we have a 
strong indication that pragmatic use of open craniotomy does not produce the presumed 
benefits. Today, when caring for the millions of spontaneous ICHs that occur yearly, 
clinicians are faced with substantial class 1 evidence demonstrating no effect of routine 
craniotomy on the functional performance of subjects experiencing brain hemorrhage. 
STICH 1 also demonstrated that subjects with deep basal ganglia hematomas were 
particularly likely to experience a poor outcome, if they underwent craniotomy. These 
findings were consistent with samples from the general population and suggest, in a 
congruent manner, that an alternate approach to ICH be considered. Small studies have 
tested the idea that catheter-based, minimally invasive clot volume reduction can be 
performed without loss of life and that individual subjects experience improved outcome in 
increased proportion. Because of the significant morbidity and mortality associated with 
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ICH, hyper acute craniotomy and deep location of ICH in particular, we chose to organize a 
two-stage test of the possibility that minimally invasive surgery, performed on stabilized 
subjects provides benefit from clot reduction without exposing patients to as much injury as 
was possibly occurring from open craniotomy. Further testing of this idea could include 
studies of the recovery process as well as larger trials.
Added value of this study
To the best of our knowledge MISTIE II is the first rigorous study of brain MIS because it 
was a multisite study with a standardized surgical task designed to eliminate cortical 
incision, electrocautery, toxic exposure to thrombin and the attendant additional loss of deep 
brain tissue. The results provide evidence of safety of the MIS approach and identify the best 
dose of thrombolytic to be employed for clot volume reduction. It identifies that you cannot 
combine MIS and alteplase without increased incidence of asymptomatic bleeding. The need 
for meticulous management of bleeding risk is inherent in this finding. In addition, results 
produced an estimate of treatment effect that is substantial (>10% absolute benefit) and 
longstanding (one year). As such, these data provide novel safety, surgical performance and 
overall proof of concept for the hypothesis that MIS has robust potential as a unique 
intervention for intracerebral hemorrhage.
Implications of all the available evidence
Although this manuscript focuses on the results of MISTIE II and the possible role of clot 
volume reduction as a mechanism of treatment, it is consistent, in a clearly defined 
prospective manner, with the external data from single site and meta-analysis of convenience 
samples. The data provide a sound basis to estimate a treatment effect and inform clinical 
goals for the surgical task of clot size reduction, if performed in the standard manner 
described (i.e., single tissue trajectory, small tissue cannula, minimal mechanical 
manipulation). The manuscript highlights the possibility that MIS is a technique with 
promise to mechanically reduce lesion size in all or many subjects and has the potential to 
directly alter the course of events set in motion by the presence of blood clot within brain 
tissue and treat a disease for which we have no therapy. Trials utilizing this approach will 
require well-defined management of bleeding risk and identification of relevance or not to 
amyloid vasculopathy. The time window for ICH trials remains broad as sub group analysis 
in MISTIE did not find benefit or detriment in the times observed. The precise role of 
clinical stability in patient selection is another subject for future trials. The findings have 
stimulated multiple smaller tests of parts of our MIS thought process with many variations 
of equipment and surgical technique. Sharing the full results of MISTIE II is likely to 
stimulate further investigations of a worldwide problem that is serious and growing. An 
investigator-initiated, publically sponsored NIH trial MISTIE 3 is underway to prospectively 
test the generalizability of the MISTIE 2 surgical task and medical stabilization protocol.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. CONSORT diagram of the MISTIE II trial
*includes 6 medical subjects from Tier III (not shown); **ITT efficacy analysis
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Figure 2. ICH removal by treatment group
This figure demonstrates the treatment effectiveness measured in terms of amount and 
timing of ICH removal. Panel A is a plot of percent of clot remaining as measured on daily 
CT scan after achieving clot size stability and initiating MIS+rt-PA, thin lines are individual 
subjects. Dense blue and red lines are the fitted average response. The gray-shaded area is 
the 95% confidence intervals of this average response. The black line identifies the average 
occurrence of the 24-hour post last treatment time point. Panel B represents the distribution 
of each subject’s clot removal expressed as absolute volume reduction on the day 4 EOT CT 
scan. The dashed line indicates the 50th percentile subject and respective ICH volume 
reduction for the medical subject cohort. The dotted line indicates the 50th percentile subject 
and respective volume reduction for this subject in the MIS+rt-PA group. All volumes were 
detrmined by the core lab. Removal is as defined in the methods.
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Table 1
Baseline Demographics and Characteristics by Treatment Group.*
Medical (N=42) MIS+rt-PA (N=54) P values
Demographic variables
  Age in Years: Mean (SD) 61.1 (12.3) 60.7 (11)
  Age in Years: Median (IQR) 62 (49.5 - 73) 60 (54 - 69)
  Gender: Male 28 (66.7%) 35 (64.8%)
  Race
    Caucasian 23 (54.8%) 30 (55.6%)
    African American 11 (26.2%) 18 (33.3%)
    Hispanic 5 (11.9%) 4 (7.4%)
    Other 3 (7.1%) 2 (3.7%)
Baseline variables
  Diabetes 11 (26.2%) 14 (25.9%)
  History of Hypertension 34 (81%) 49 (90.7%)
  Other Cardiovascular Disease 14 (33.3%) 22 (40.7%)
  Alcohol Abuse 7 (16.7%) 17 (31.5%)
  Presentation Blood Pressure
    Systolic BP (mmHg): Mean (SD) 186.7 (34.1) 186.4 (33.0)
    Diastolic BP (mmHg): Mean (SD) 101.9 (20.4) 106.8 (27.7)
  Enrollment GCS
    3–8 13 (31%) 17 (31.5%)
    9–12 12 (28.6%) 20 (37%)
    13–15 17 (40.5%) 17 (31.5%)
  Enrollment NIHSS: Mean (SD) 21.6 (8.9) 22.8 (8.5)
  Enrollment NIHSS: Median (IQR) 21 (17 - 27) 22 (18 - 29)
  Stability CT (last CT prior to enrollment)
    ICH Volume (mL): Mean (SD) 43.1 (15.3) 48.2 (19.6)
    ICH Volume (mL): Median (IQR) 41.4 (33.2 - 50) 43.4 (31.6 - 59.3)
    IVH Volume (mL): Mean (SD) 2.4 (3.9) 4.6 (7.7)
    IVH Volume (mL): Median (IQR) 0.7 (0 - 3.1) 0.8 (0 - 4.4)
  Clot Location
    Lobar 15 (35.7%) 18 (33.3%)
    Deep 27 (64.3%) 36 (66.7%)
Treatment variables
  % With ICP monitoring 10 (23.8%) 9 (16.7%) 0.444
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Medical (N=42) MIS+rt-PA (N=54) P values
  % Ventilated 16 (38.1%) 25 (46.3%) 0.533
  Time from Ictus to Randomization (Days) 1.3 (0.6) 1.2 (0.5) 0.174
  Systolic BP (mmHg): Mean (SD) 145.3 (20.7) 143.9 (21.1) 0.741
  Diastolic BP (mmHg): Mean (SD) 73 (14.9) 71.2 (13.1) 0.534
  Time from Randomization to Surgery
(Hours) 6.6 (7.8)
  Surgery (elapsed time from symptom
onset)
    ≤ 36 Hours 31 (57.4%)
    > 36 Hours 23 (42.6%)
  Number of Doses of rt-PA: Median (IQR) 3.5 (2 - 5.8)
  Days in ICU (IQR)† 8 (5–13) 8 (6–15) 0.839
  Days to return home (IQR)‡ 89 (54–146) 51 (36–89) 0.031
*SD, Standard deviation; IQR, inter-quartile range. Unless otherwise specified, the values are expressed as count and % within group.
†
P=0.839 comparing medical to MIS+rt-PA.
‡
P=0.031 comparing medical to MIS+rt-PA
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Table 3
Functional Outcome Showing Modified Rankin Scale Scores at Days 180 and 365 Comparing MISTIE 
Treatment vs. Medical Controls for All Randomized subjects.
Treatment Group
Day 180*
Treatment Group
Day 365**
mRS Score
Medical
(N=42)
MIS+rt-PA
(N=54)
Medical
(N=31)
MIS+rt-PA
(N=25)
0 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (4.0%)
1 0 (0.0%) 1 (1.9%) 1 (3.2%) 3 (12.0%)
2 4 (9.5%) 6 (11.1%) 2 (6.5%) 2 (8.0%)
3 5 (11.9%) 11 (20.4%) 3 (9.7%) 2 (8.0%)
4 12 (28.6%) 13 (24.1%) 6 (19.4%) 3 (12.0%)
5 6 (14.3%) 7 (13.0%) 3 (9.7%) 2 (8.0%)
6 11 (26.2%) 14 (25.9%) 11 (35.5%) 10 (40.0%)
Missing 4 (9.5%) 2 (3.7%) 5 (16.1%) 2 (8.0%)
*
Includes participants from primary analysis set (which includes randomized patients from stages one and two). For graphical display see 
Supplement Figure S4.
**
Includes only randomized participants enrolled in stage two, i.e., those enrolled after protocol change extending follow-up to 365 days.
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